According to a new market report published by Transparency Market Research “Pulmonary Arterial Hypertension (PAH) Market (Prostacyclin and Prostacyclin Analogs, ERAs, PDE-5 Inhibitors, sGC Stimulators and Selexipag) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 – 2020,” the global PAH market was valued at USD 4.04 billion in 2013 and is expected to grow at a CAGR of 2.3% from 2014 to 2020, to reach an estimated value of USD 5.19 billion in 2020.
Browse the full Pulmonary Arterial Hypertension (PAH) Market Report: http://www.transparencymarketresearch.com/pulmonary-arterial-hypertension-therapeutics.html
Pulmonary arterial hypertension (PAH) is a type of pulmonary hypertension that gets severe over time. PAH is characterized by high blood pressure in pulmonary arteries, however, it is different from having regular high blood pressure. It occurs when pulmonary arteries become narrow in diameter or get blocked. The available medications to treat PAH can only reduce symptoms, improve the quality of life, and slow down disease progression so that a patient with PAH can better with the disease. Prostacyclin and prostacyclin analogs, endothelin receptor antagonists (ERAs), and phosphodiesterase-5 (PDE-5) inhibitors are some major drug classes that are prescribed to patients suffering from PAH.
North America represented the largest regional market for PAH in 2013, with a revenue share of 44.6%. The U.S. and Canada are the two major markets of this region. During the forecast period between 2014 and 2020, the North American market for PAH therapeutics is expected to be driven by factors such as the introduction of newly-approved drugs and increasing market penetration by big pharmaceutical companies. In 2013, three drugs indicated for the treatment of PAH were approved by the U.S. FDA. These drugs are Opsumit (macitentan), Orenitram (treprostinil extended release), and Adempas (riociguat). The North American market witnessed the entry of a multibillion dollar company, Bayer HealthCare with its proprietary PAH drug Adempas. Various sources including WHO and CDC indicate that PAH affects nearly 30,000 people in the U.S. It is likely that a number of cases go undiagnosed due to non-specific symptoms of PAH such as shortness of breath, fatigue, and syncope.
In December 2013, the European Commission granted marketing authorization to Actelion Pharmaceuticals, Ltd. for the use of Opsumit (macitentan) in the treatment of PAH. Opsumit can be administered as monotherapy or in combination with other drugs indicated for PAH treatment. In March 2014, the European Commission approved the use of Adempas in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) and PAH. These two new drugs are expected to generate significant revenue during the forecast period between 2014 and 2020, thereby driving market growth. The European PAH market would be further driven by the anticipated launch of Uptravi (selexipag) in 2016.
Browse the full Press Release of this report: http://www.transparencymarketresearch.com/pressrelease/pulmonary-arterial-hypertension-therapeutics-market.htm
Asia-Pacific held the third-largest share (13.0%) in the global PAH market in 2013, after North America and Europe. Though this region has a relatively large population of patients with PAH; hospitals, diagnostic centers, and physicians have limited experience with PAH diagnosis and treatment. Over the forecast period between 2014 and 2020, growing awareness regarding PAH diagnosis and treatment is likely to play a key role in the growth of the PAH market in the region.Rest of the World (ROW) includes Latin America, the Middle East, and Africa. Latin America includes the Central and South American countries such as Mexico, Brazil, Argentina, Venezuela, and Chile. Some of the major factors that are expected to drive market growth include rising health care expenditure, constantly improving health care infrastructure, and rising awareness regarding PAH. On the other hand, the high cost associated with PAH treatment compels physicians to prescribe support therapy to patients rather than PAH-specific therapy. It is primarily because majority of the patients in this region are unable to afford the treatment due to low disposable incomes.
Some major players operating in the PAH market include Actelion Pharmaceuticals, Ltd., Bayer HealthCare, Gilead Sciences, Inc., GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc. and United Therapeutics Corporation.
The global PAH market is segmented as follows:
Global Pulmonary Arterial Hypertension Market, by Drug Class
- Prostacyclin and Prostacyclin Analogs
- Endothelin Receptor Antagonists (ERAs)
- Phosphodiesterase-5 (PDE-5) Inhibitors
- Soluble Guanylate Cyclase (sGC) Stimulators
Pipeline Analysis: Pulmonary Arterial Hypertension Market
- Early-stage Drug Candidates (Phase I & Phase II)
- Late-stage Drug Candidates (Phase III & Registration Phase)
Global Pulmonary Arterial Hypertension Market, by Geography
- North America
- Rest of the World (RoW)
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Mr. Nachiket Ghumare
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453